Zymeworks' Theravance Buy: Revenue, Pipeline, and Platform Readthrough

Zymeworks is buying Theravance Biopharma in a deal that combines its antibody-drug conjugate platform with a revenue-generating respiratory business, according to the company's M&A call transcript.

CEO Ken Galbraith said the acquisition gives Zymeworks an immediate revenue stream from Theravance's marketed products, reducing its reliance on partnership milestones. Theravance brings cash flows from its commercial respiratory franchise, which will help fund Zymeworks' pipeline through late-stage trials.

Chief Financial Officer Kristin Stafford outlined a non-recourse financing arrangement with OMERS Life Sciences. The structure limits Zymeworks' downside exposure if the deal underperforms, she said.

The acquisition is a read-through for other platform biotechs with thin revenue. Zymeworks is buying a profitable business to self-fund R&D, a structure that could become more common if biotech M&A faces a tight financing environment. Analysts from Citigroup and Wells Fargo pressed management on integration risk and the potential for further bolt-on acquisitions, according to the transcript.

Zymeworks carries an Alpha Score of 43, a mixed signal on the system. The score reflects the uncertainty around pipeline execution offset by the balance sheet improvement from the acquisition. For investors, the open question is whether Theravance's commercial infrastructure can translate into value for Zymeworks' own ADC candidates.

The transaction will be funded through cash on hand and the non-recourse OMERS facility, Stafford said. Subject to customary approvals, the companies expect to close in the third quarter.